Chronic granulocytic leukemia is a malignant myeloproliferative neoplasm occurring in pluripotent hematopoietic stem cells, focusing on the treatment of chronic phase and early stage. Currently, the main therapeutic measure for chronic granulocytic leukemia is molecular targeted therapy, including first-generation targeted drugs and second- and third-generation targeted drugs. 1. Imatinib, a first-generation targeted drug, is commonly used and should be used for at least 3 years, and maintained for more than 2 years after achieving good efficacy. 2. Second-generation drugs such as nilotinib, dasatinib, etc., and third-generation drugs such as ponatinib, etc., should be used for at least 3 years, and maintained for more than 1 year after good efficacy is achieved. The vast majority of patients need lifelong medication. It is recommended to go to the hematology department of regular hospitals in a timely manner, under the guidance of specialists to use medication, usually pay more attention to rest, avoid mental stress and overwork, adjust the routine of life and work, do a good job of personal hygiene, more disinfection at home, to prevent infections, and a reasonable combination of meals, to ensure balanced nutrition.